Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

SHILPA MEDICARE LTD. - 530549 - Compliance Requirement Of The Company And Certify That The Company Has Maintained A Structured Digital Database (SDD) Pursuant To Provisions Of Regulation 3(5) And 3(6) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015

 Compliance requirement of the Company and certify that the Company has maintained a Structured Digital Database (SDD) pursuant to provisions of Regulation 3(5) and 3(6) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
09-08-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for To Inter-Alia Consider The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30Th June 2022

 SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2022 ,inter alia, to consider and approve Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June 2022
03-08-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited, Unit III, Advanced Analytical Characterization Laboratory Clears US FDA Remote Record Review

 This is to inform you that US FDA has concluded Remote Record Review of Shilpa Medicare Limited ('SML' or 'the Company'), Unit III, Advanced Analytical Characterization Laboratory situated at Dabaspet, Bengaluru, Karnataka without any objectionable conditions or observations. The review was conducted during 15th to 18th Nov 2021. The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing, Nitrosamine testing, Elemental Impurity testing, Extractable & Leachable testing, Glass Delamination testing etc.
29-07-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited Has Received Russian GMP For Unit I, Raichur API Facility.

 This is to inform that the Company's API facility (unit-1) located at Raichur, Karnataka has received GMP certificate from MOH-Russia. The facility was audited by the agency on 17 February 2022, 18 February 2022 and 21 February 2022. The facility involves in manufacturing, testing, packing, storage of chemically synthesized non-sterile drug substances for human use.
16-07-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Intimation U/R 30 Of The SEBI(Listing Obligations & Disclosure Requirements) Regulations, 2015

 Shilpa Medicare Limited, Unit VI, Bengaluru facility has been issued UK MHRA GMP
12-07-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Intimation U/R 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Shilpa Medicare Limited, Unit VI, Bengaluru facility has been issued UK MHRA GMP
12-07-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Please find attached copies of certificates sent to Central Depository Services (India) Limited and National Securities Depository Limited under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30.06.2022.
11-07-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Statement Of Investor Complaints For The Quarter Ended June 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- RITU TIWARYDesignation :- Company Secretary and Compliance Officer
11-07-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Appointment of Dr. Kamal K Sharma (DIN: 00209430) as an Additional Independent Director of the Company w.e.f. 01st July, 2022
01-07-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Update On Slump Sale Of Active Pharmaceutical Ingredient Business Of The Company

 We hereby wish to inform that the Company has duly executed the Business Transfer agreement with Shilpa Pharma Lifesciences Limited (Formerly known as Shilpa Corporate Holdings Private Limited) the transferee Company which is complete and effective from 30 June 2022, closing of business hours.
01-07-2022
Next Page
Close

Let's Open Free Demat Account